Navigation Links
Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
Date:7/29/2011

versus $642 million in the second quarter of 2010.  This increase reflected the costs associated with late stage clinical programs, particularly the Phase 3 trials for AMG 386, AMG 479 and OncoVEX(GM-CSF) (talimogene laherparepvec).  R&D expenses were also driven by increased support for our marketed products and by an increase in discovery research and early pipeline activities.  For the full year, adjusted R&D expenses are expected to be at the upper end of the range of 18 to 20 percent of product sales.

Selling, General & Administrative (SG&A) expenses increased 15 percent to $1,111 million in the second quarter of 2011 versus $968 million in the second quarter of 2010.  This increase was driven by the U.S. Healthcare Reform Federal Excise Fee of $47 million; higher ENBREL profit share expenses of $40 million due to increased ENBREL sales; and higher spending related to the launches of Prolia and XGEVA, as well as expansion of our international operations.

The adjusted tax rate for the second quarter of 2011 was 15.2 percent compared to 20.0 percent for the second quarter of 2010.  The decrease was due primarily to the recognition of foreign tax credits associated with the new Puerto Rico excise tax effective in 2011 and the benefit of the federal R&D credit in the second quarter of 2011 that was not in effect for the second quarter of 2010, partially offset by the impact of the non-deductible U.S. Healthcare Reform Fee.  Excluding the impact of the Puerto Rico excise tax, the adjusted tax rate for the second quarter of 2011 would have been 20.3 percent.

Average diluted shares for adjusted EPS for the second quarter of 2011 were 934 million versus 964 million for the second quarter of 2010.

Capital expenditures for the second quarter of 2011 were $123 million versus $177 million in the second quarter of 2010.  Operating cash flow for the second quarter of 2011 decreased to
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
3. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Massachusetts y LONDRES, August 30, 2015 /PRNewswire/ ... ofrece una visión holística de l ... todo el trayecto   ... hoy el debut europeo de IntelliSpace Cardiovascular , ... que ofrece sofisticadas herramientas para acceder, analizar y compartir ...
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... NEW YORK, April 28, 2011 Reportlinker.com ... is available in its catalogue: ... Healthcare System and Drug Regulatory Overview: Cost-containment ... http://www.reportlinker.com/p0487111/Pharmaceutical-Key-Trends-2011---Healthcare-System-and-Drug-Regulatory-Overview-Cost-containment-and-regulatory-pressures-intensify.html ...
... 28, 2011 West Pharmaceutical Services, Inc. (NYSE: ... quarter of 2011.  Summary comparative results were as follows:($ millions, ... 295.4 , $ 274.7Gross Profit , 88.0 , 82.2Reported Operating ... 30.7 , 29.5Reported Diluted EPS , $ 0.56 , $ ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 5Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 6West Announces First Quarter 2011 Results 2West Announces First Quarter 2011 Results 3West Announces First Quarter 2011 Results 4West Announces First Quarter 2011 Results 5West Announces First Quarter 2011 Results 6West Announces First Quarter 2011 Results 7West Announces First Quarter 2011 Results 8West Announces First Quarter 2011 Results 9West Announces First Quarter 2011 Results 10West Announces First Quarter 2011 Results 11West Announces First Quarter 2011 Results 12West Announces First Quarter 2011 Results 13West Announces First Quarter 2011 Results 14
(Date:8/31/2015)... ... 31, 2015 , ... CareSource, a nonprofit Ohio-based health plan, ... capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and ... have contributed to the company’s rapid growth. As the CareSource business model expands ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Bay Pines VA Healthcare System ... southwest Florida by hiring more doctors and nurses and expanding existing facilities and services. ... In early July, Dr. Anthony Jabre was selected to lead and grow the Bay ...
(Date:8/31/2015)... , ... September 01, 2015 , ... ... Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. ... breakthrough. Traumatic brain injury has been largely untreatable - with mostly palliative treatments ...
(Date:8/31/2015)... ... 2015 , ... Since 1946, the doctors and staff at Clifton Dental Associates ... patient arrives at the office, the staff will make them feel welcome and comfortable. ... to create a complete dental treatment plan that is unique to each smile! ...
(Date:8/31/2015)... ... ... LUT Soft pack from Pixel Film Studios, editors can quickly and easily add soft color ... modifying an image. The LUT changes every pixel's color to the corresponding color indicated by ... requires Final Cut Pro X 10.2 or newer. , By manipulating each pixel, LUTs ...
Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2
... , ... amongst the first to utilize cutting edge high definition technology for patients with visual impairments. ... (PRWEB) February 3, ... of recent technological advancements in eye surgery. In addition to promising 20/20 vision, new corrective ...
... ... received approval for re-accreditation by the American College of Radiology (ACR) , ... Berkeley Heights (Vocus) February 2, ... American College of Radiology (ACR) for the period of January 2010 through January 2013. ...
... , ... cigarette brand Intellicig has signed an exclusive deal which will see their products stocked ... Distribution and Smiths News. , ... (PRWeb UK) February 2, 2010 -- Leading electronic cigarette brand Intellicig has ...
... , NEW YORK , Feb. 2 ... organization, will host its first charity fundraiser at Jonathan in ... event will launch a much needed organization whose sole purpose is ... and to administer compassionate patient counseling. , Founder Melissa A. ...
... all human embryonic stem cell lines being used in 2005 ... left traces on the human cells. If those cells had ... been rejected by the patient,s immune system. Even today, ... research, there remains a risk that these cells will be ...
... suggested one scan is usually enough, but editorial begs to ... for a paper in a medical journal to be accompanied ... paper might be "overly simple and consequently not clinically useful." ... Feb. 3 issue of the Journal of the American ...
Cached Medicine News:Health News:HD For More Than Your TV – New Technologies Offer Patients High Definition Vision At Any Age 2Health News:Nuclear Medicine at Summit Medical Group Earns ACR Re-Accreditation 2Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 2Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 3Health News:February Fundraiser Launches Cohen Esophageal Cancer Initiative (CECI) 2Health News:3-D scaffold provides clean, biodegradable structure for stem cell growth 2Health News:3-D scaffold provides clean, biodegradable structure for stem cell growth 3Health News:Analysis Examines Ultrasound Use for Blood Clots 2Health News:Analysis Examines Ultrasound Use for Blood Clots 3
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... only catheter of its kind, the ... collects real-time cardiac electrical information, translating ... With 64 electrodes, this unique tool ... than 3,000 points of electrical data ...
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
Medicine Products: